The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma.
about
Deficient spindle assembly checkpoint in multiple myelomaAntineoplastic effects of an Aurora B kinase inhibitor in breast cancer.A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myelomaTG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cellsUpdate on aurora kinase inhibitors in gynecologic malignancies.Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer.Update on Aurora Kinase Targeted Therapeutics in Oncology.Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancerAurora B kinase is a potent and selective target in MYCN-driven neuroblastomaAurora kinase inhibitors as anticancer molecules.The potential role of Aurora kinase inhibitors in haematological malignancies.Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myelomaCentrosomes and myeloma; aneuploidy and proliferation.Inhibition of Aurora-B suppresses osteosarcoma cell migration and invasion.Kinase inhibitors as potential agents in the treatment of multiple myeloma.Novel therapeutic targets for multiple myeloma.From cell biology to therapy: ENMD-2076 in the treatment of multiple myeloma.ENMD-2076 for hematological malignancies.Targeting syndecans: a promising strategy for the treatment of cancer.Mitosis as an anti-cancer drug target.Histone modifying enzymes: novel disease biomarkers and assay development.The Aurora kinase inhibitors in cancer research and therapy.EBNA3C regulates p53 through induction of Aurora kinase B.Aurora B inhibitor barasertib and cytarabine exert a greater-than-additive cytotoxicity in acute myeloid leukemia cells.Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imagingThe therapeutic potential of cell cycle targeting in multiple myeloma.Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA.A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191.Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma
P2860
Q21560908-F3967A60-B264-4B90-9221-47DA0E6758D4Q33732173-C11B571C-B4C6-4C6D-BE47-50A8424EEE12Q33944281-D2F81434-26E7-4CDF-90A1-1864F2FB9637Q34134557-37C4BDFF-CFB1-43A3-9E01-6E43AD9E5D39Q34576017-E7AED3E1-0B86-4674-933B-6247F7B5D272Q34621867-9DBB3ED1-D57D-41C9-B9EC-166EA6505AC2Q34941504-500E73B3-8EC0-4B0E-99ED-635D00A5DCB8Q35356178-1626EAF9-C350-4C7D-81BC-C5C420A75C64Q35819646-F6944BAD-693C-4D02-9F3B-F61DE4A12014Q35850203-295FE1C2-9A68-44BC-8103-34206778957FQ37167047-EA942D74-F777-4793-8414-6A4507F4EE78Q37237509-9C24F323-5D5C-44E7-948A-18446D53FAB0Q37384474-645F2163-36F8-4FCB-AAFF-32B0F74DAA2CQ37575064-2D8FB29B-DDB3-4A52-B2D5-C4F382F50A00Q37697253-BB01E019-AA8A-49D1-8568-3AFA2E92C8DEQ37707383-92978443-9ACB-49F0-BDDF-7E48D58413D1Q37880074-A6D90C45-47EB-4B11-8985-17A555D89759Q37991379-A505E50A-081D-49EE-8A5A-18CF75A12703Q38082795-75F5DABB-8F35-48D4-B837-C02FE8E0AF21Q38115166-114E595F-2385-4FC0-8F41-079C4C691098Q38691865-84EF8100-5978-455B-B2CC-38C85BF32A80Q38756932-6A6F09A1-F9AD-4AE0-AFC4-E3D97796DA9FQ38908573-D698F3DE-B60A-47CD-B833-5E19AFC21294Q39171321-15CEA11E-264B-420E-8525-1A57340D568CQ39571840-AA1B9ACB-B6AD-4DDB-9EA6-FFF13D120D14Q39606309-2B9A727A-98DF-4961-8363-6AE9178CEF86Q47203904-5B7F9A1F-077D-40DD-8CB2-CCC0DD6C43D8Q48213066-1763DEF2-6231-48C3-8519-090C8D90697AQ53817434-D49B76C9-4B01-4D57-91D1-B2C5861BD37DQ57818334-64749229-966D-4E1A-BEDB-D3DBD5C00B4A
P2860
The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The selective Aurora B kinase ...... reatment for multiple myeloma.
@en
type
label
The selective Aurora B kinase ...... reatment for multiple myeloma.
@en
prefLabel
The selective Aurora B kinase ...... reatment for multiple myeloma.
@en
P2093
P2860
P1476
The selective Aurora B kinase ...... treatment for multiple myeloma
@en
P2093
Andrew R Belch
Claudia Naber
Linda M Pilarski
Raymond Lai
Robert P Evans
Tamara Checkland
Tara Steffler
Tony Reiman
P2860
P304
P356
10.1111/J.1365-2141.2007.06913.X
P407
P577
2007-12-10T00:00:00Z